BioMarin Pharmaceutical Inc. has entered into a definitive agreement to acquire Amicus Therapeutics for approximately $4.8 billion in an all-cash transaction. The agreement has been approved by the Boards of Directors of both companies. The transaction is expected to close in 2Q26, subject to customary closing conditions.

“Amicus, like BioMarin, has been dedicated to transforming care for patients with rare diseases, developing and bringing to market therapies for individuals living with Fabry disease and Pompe disease. BioMarin’s scale of operations, including our global commercial footprint and industry-leading, in-house manufacturing capabilities make the combination of these companies an exceptional strategic fit,” said Alexander Hardy, President and Chief Executive Officer of BioMarin. 

“I am enormously proud of our Amicus team. Together with our partners in the rare disease community, we created a patient-centric biotech and successfully developed two transformative medicines for people living with rare diseases, which impacted the lives of more than 3,400 patients around the world,” said Bradley L. Campbell, President and Chief Executive Officer of Amicus. “With BioMarin’s greater resources and scale, Amicus’ medicines will reach even more patients around the world, faster.”